Cointime

Sapience Therapeutics

company

About

Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs

  • 1 - 10

Highlights

Total Funding Amount
$63.50M
Funding Rounds
3
Investors
3

Details

Last Funding Type
Series B
Last Funding Money Raised
$41M
Industries
Biotechnology,Medical,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer.

The company was founded in 2015 by Barry Kappel and is based in Scarsdale, New York, United States.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$63.50M
Sapience Therapeutics has raised a total of $63.50M in funding over 2 rounds. Their latest funding was raised on May 31, 2022 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 31, 2022 Series B $41M 1 NexPoint — Detail
Dec 1, 2021 Convertable Note — 1 NexPoint — Detail
Jul 12, 2016 Series A $22.50M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
2
3
Sapience Therapeutics is funded by 3 investors. NexPoint and TaiAn Technologies are the most recent investors.
Investor Name Lead Investor Funding Round
NexPoint Yes Series B
TaiAn Technologies — Series A
Healthlink Capital — Series A
Cointime
เนื้อหา
บริษัท